Curiox Biosystems Valuation

Is A445680 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A445680 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A445680's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A445680's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A445680?

Key metric: As A445680 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A445680. This is calculated by dividing A445680's market cap by their current book value.
What is A445680's PB Ratio?
PB Ratio	6.4x
Book	₩48.81b
Market Cap	₩313.24b

A445680 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	52.8x
Enterprise Value/EBITDA	-30.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A445680's PB Ratio compare to its peers?

The above table shows the PB ratio for A445680 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.6x
A220100 FutureChemLtd	6.1x	n/a	₩357.7b
A278650 HLB bioStepLtd	1.6x	n/a	₩181.9b
A038290 Macrogen	1.1x	108.1%	₩160.7b
A039860 NanoEntek	1.5x	n/a	₩107.6b
A445680 Curiox Biosystems	6.4x	n/a	₩313.2b

Price-To-Book vs Peers: A445680 is expensive based on its Price-To-Book Ratio (6.4x) compared to the peer average (2.6x).

Price to Book Ratio vs Industry

How does A445680's PB Ratio compare vs other companies in the KR Life Sciences Industry?

1 Company	Price / Book	Estimated Growth	Market Cap
A225220 Genolution	0.5x	n/a	US$31.97m

No more companies available in this PB range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: A445680 is expensive based on its Price-To-Book Ratio (6.4x) compared to the KR Life Sciences industry average (1.4x).

Price to Book Ratio vs Fair Ratio

What is A445680's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A445680 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	6.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A445680's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

0.9%

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

-5.8%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

1.7%

-39.0%